

IAPG Rec'd PCT/PTO 28 SEP 2006

PTO-1390 (Rev. 09-2006)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 50425/262
INTERNATIONAL APPLICATION NO. PCT/US2005/010521	INTERNATIONAL FILING DATE March 29, 2005	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/594641
TITLE OF INVENTION TREATMENT OF TYPE 1 DIABETES WITH INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR		
APPLICANT(S) FOR DO/EO/US Yousef Al-Abed		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p>		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.6)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/594641	PCT/US2005/010521	50425/262

20. Other items or information: cover letter and return receipt postcard (enclosed)

The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic national fee (37 CFR 1.492(a)).....				\$ 300	
22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4). \$0 All other situations..... \$200				\$ 200	
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4). \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... \$400 All other situations..... \$500				\$ 100	
TOTAL OF 21, 22 and 23 =				\$ 600	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) in an electronic medium or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
54 - 100 =	0 /50 =		x \$250	\$ 0	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$	
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims		19 - 20 =	0	x \$ 50	\$ 0
Independent claims		2 - 3 =	0	x \$200	\$ 0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 600	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.					
				SUBTOTAL =	\$ 300
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				+	\$
				TOTAL NATIONAL FEE =	\$ 300
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
				TOTAL FEES ENCLOSED =	\$ 300
				Amount to be refunded:	\$
				Amount to be charged	\$

10/594641

AR&E Docket No. 50425/262

PTO-1390 (Rev. 09-2006)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

IAP2 Rec'd PCT/PTO 28 SEP 2006


- a. A check in the amount of \$ 300.00 to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-1785. A duplicate copy of this sheet is enclosed.
- d. Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038. The PTO-2038 should only be mailed or faxed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO.

ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be advised that this is not recommended and by doing so your credit card information may be displayed via PAIR. To protect your information, it is recommended paying fees online by using the electronic payment method.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Craig J. Arnold, Esq.
Amster, Rothstein & Ebenstein LLP
90 Park Avenue
New York, NY 10016



SIGNATURE

Elie H. Gendloff

NAME

44,704


REGISTRATION NUMBER

"Express Mail" mailing label No. EV_800500785.US

Date of Deposit: September 28, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Elie H. Gendloff

Signature: 

10/594641
IAP6 Rec'd PCT/PTO 28 SEP 2006

Partners	Associates	Benjamin M. Halpern*
Morton Amster Jesse Rothstein (1934 - 2003) Daniel Ebenstein Philip H. Gottfried Michael J. Berger Neil M. Zipkin Anthony F. Lo Cicero Kenneth P. George Abraham Kasdan, Ph.D. Ira E. Silfin Chester Rothstein Craig J. Arnold Kenneth M. Bernstein Joseph M. Casino	Charles R. Macedo Michael V. Solomita Patrick Boland* John S. Economou Holly Pekowsky Michael P. Kenney Marion P. Metelski Max Vern Karl J. Kolbinger	Brian A. Comack Richard S. Mandaro Marc J. Jason Elie H. Gendloff, Ph.D. David Mitnick Charles W. Rath David A. Boag Mathieu Hausig Jung S. Hahn Reiko Kaji Alan D. Miller, Ph.D. John A. Lepore Norajean McCaffrey
		Matthew A. Fox Michael J. Kasdan Rebecca R. Eisenberg Stuart Shapley Howard Wizenfeld
		<small>*Not admitted in New York</small>

AMSTER ROTHSTEIN & EBENSTEIN LLP

Intellectual Property Law


90 Park Avenue
New York NY 10016
Main 212 336 8000
Fax 212 336 8001
Web www.arelaw.com

September 28, 2006

Elie H. Gendloff, Ph.D., Esq.
Direct 212 336 8108
E-mail egendlof@arelaw.com

Via Express Mail
(EV 800500785 US)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

"Express Mail" mailing label No.	EV 800500785 US
Date of Deposit:	September 28, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

Re: United States National Phase Filing of
PCT Application PCT/US2005/010521
Title: TREATMENT OF TYPE 1 DIABETES WITH INHIBITORS
OF MACROPHAGE MIGRATION INHIBITORY FACTOR
Applicant: Yousef Al-Abed
Our File: 50425/262

Dear Sir:

Pursuant to 35 U.S.C. § 371 and 37 C.F.R. § 1.495, enclosed please find an application for patent in the name of Yousef Al-Abed, entitled "TREATMENT OF TYPE 1 DIABETES WITH INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR," for entering the national phase in the United States of America, comprising the following:

1. a "Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. § 371," Form PTO-1390 (3 pages with 3rd page in duplicate);
2. a Preliminary Amendment (6 pages);
3. a copy of PCT Application No. PCT/US2005/010521 as published under PCT Publication No. WO 2005/094338 A2, including cover page with Abstract (1 page), specification (39 pages), claims (5 pages) and drawings (9 sheets);

10/594641

IAP2 Rec'd PCT/PTO 28 SEP 2006

Commissioner for Patents
Alexandria, VA 22313-1450
Mail Stop PCT

-2-

September 28, 2006

4. an AR&E check in the amount of \$300 to cover the total filing fees, claiming small entity status; and
5. a return receipt postcard.

Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

Amster, Rothstein & Ebenstein LLP
Attorneys for Applicants
90 Park Avenue
New York, NY 10016
212 336 8000

By: 
Elie Gendloff
Registration No. 44,704

Dated: New York, New York
September 28, 2006